$STRS

Mon: TASE claws back strong early losses

Israel and Iran reportedly agreed to stop hostilities under US pressure, helping the Tel Aviv Stock Exchange rebound from early losses. The TA-35 rose 0.33% to 4,281.85 and TA-125 rose 0.01% to 4,232.14; BlueTech Global fell 0.86% to 696.72. Insurance gained 2.2%; TelBond 60 was flat. Turnover: NIS 4.80b equities, NIS 5.43b bonds. Shekel strengthened to NIS 2.943/$ and NIS 3.39/€.

Original reporting
Published Jun 9, 2026, 12:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 9, 2026, 1:18 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Mon: TASE claws back strong early losses — source image
Decision brief

The 30-second read

$STRSBullishLow
01

Why it matters

The newest concrete fact is the market’s reaction to cease-hostilities clarity; company moves are presented as part of that tape rather than standalone fundamentals.

02

Market read

Useful for gauging intraday risk sentiment and which Tel Aviv sectors/names are trading as proxies, but it contains no new issuer-specific fundamentals.

03

What to watch

The article is a market wrap with no company-specific catalysts; traders should treat moves as correlation trades and wait for follow-through from subsequent sessions or filings.

Relevance 4/10Novelty 2/10Timing: during the Tel Aviv session (morning losses then rebound)

Background

The session is framed around a shift in Israel-Iran hostilities expectations after US pressure, with indices mixed and turnover reported.

Company-level read

Ticker impact

$STRSBullishLow confidence
Context

Strauss Group jumped 4.19%, the biggest rise on the Tel Aviv 35 Index during the market’s recovery from early losses.

Expected impact

Momentum may persist intraday, but reversal risk is elevated without a fundamental trigger.

Evidence & confidence

The article frames the move within the broader market rebound; no new Strauss disclosure.

$ENLTBullishLow confidence
Context

Enlight Renewable Energy rose 1.08% during the rebound, with no separate company-specific development cited.

Expected impact

Limited conviction beyond market beta.

Evidence & confidence

The text provides only an intraday move and macro backdrop.

$ESLTBullishLow confidence
Context

Elbit Systems rose 1.89% as the market recovered on expectations of reduced hostilities between Israel and Iran.

Expected impact

Short-term upside while de-escalation holds; could reverse if security risk returns.

Evidence & confidence

Move is plausibly macro-driven; no Elbit-specific disclosure is included.

$TEVABullishLow confidence
Context

Teva Pharmaceutical rose 2.26% during the rebound after Israel-Iran cease-hostilities clarity under US pressure.

Expected impact

Near-term support if risk sentiment stays constructive.

Evidence & confidence

Only same-day price action is reported; catalyst is macro.

$TSEMBearishLow confidence
Context

Tower Semiconductor fell 4.73% for the biggest drop on the Tel Aviv 35 Index despite the overall market rebound.

Expected impact

Higher volatility/mean-reversion risk; direction depends on whether the selloff is headline- or flow-driven.

Evidence & confidence

The text cites only the intraday decline and macro backdrop, without a TSEM catalyst.

$CAMTBearishLow confidence
Context

Camtek fell 2.33% as the Tel Aviv market was mixed, with some names diverging from the rebound.

Expected impact

Could stabilize if broader risk-on continues; otherwise may lag.

Evidence & confidence

No company-specific information beyond the price move.

$ICLBearishLow confidence
Context

ICL fell 1.49% as Tower Semiconductor and other names declined while the broader market recovered.

Expected impact

Choppy near-term; watch for correlation with regional risk headlines.

Evidence & confidence

The article provides no ICL-specific news beyond the price move.

Market effects

Insurance strength (Insurance Index +2.2%) and divergence in defense/industrial names suggest sector rotation tied to regional risk sentiment.

Tel Aviv indices recovered after US pressure led Israel and Iran to cease hostilities, improving near-term risk appetite.

Limited direct global spillover in the text; primarily a regional risk-sentiment read-through.

Counterpoint

The rebound may be headline-driven and therefore fragile; single-name divergence (e.g., TSEM -4.73%) hints at positioning/sector flows beyond the macro de-escalation story.

Key entities

  • Tel Aviv Stock Exchange

    Indices recovered from early losses after cease-hostilities clarity between Israel and Iran.

  • Israel and Iran

    Bowed to US pressure to cease hostilities, driving risk sentiment in Tel Aviv.

Related articles

$ALCLow

Here's How Trump's Drug Deals Are Likely to Impact Healthcare ETFs

President Trump expanded drug-pricing agreements with 9 international companies, including Alcon and Teva, adding to 17 prior deals with firms like Pfizer. The MFN framework now covers 89% of the branded drug market. The impact on healthcare ETFs is mixed, with potential benefits for insurers (IHF) and uncertain effects on U.S. pharma (PPH).

$TEVAMed

S&P upgrades Teva rating on deleveraging and pipeline strength

S&P Global Ratings upgraded Teva Pharmaceutical Industries Ltd. to 'BBB-' from 'BB+', citing strong branded products, generics stabilization, and debt reduction. Teva's key brands generated $3.1B in 2025, with expected growth. The company reduced debt from $29B in 2018 to $17B in 2025 and aims for mid-3x leverage by year-end. S&P forecasts strong cash flow and debt reduction.

$TSEMHigh

Tower Semiconductor TSEM Draws Bullish Targets On AI Photonics

Tower Semiconductor (TSEM) shares rose 7.85% after announcing a capacity expansion and new partnerships. The company's stock closed at $222.34, below the Street's consensus target of $314.88. BofA Securities initiated coverage with a Buy rating and a $367 target, citing growth in silicon photonics for AI data centers. TSEM's revenue is expected to double in 2026, driving trader interest.

$TEVAMed

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Teva Pharmaceuticals (TEVA) agreed to a stalking-horse bid of up to $125M for BioXcel Therapeutics' (BTAI) assets, including $57.5M in cash and up to $67.5M in contingent payments. The deal, subject to court approval, includes IGALMI and other assets. The FDA has a 2026 target date for a supplemental application to expand IGALMI's label to at-home use. Competing bids may arise.

$TEVAMed

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

S&P Global Ratings upgraded Teva Pharmaceutical's long-term issuer credit rating to BBB- from BB+, reflecting strong financial performance and debt reduction. This is the third upgrade in recent months, with Teva now holding investment-grade ratings from all major agencies. The company's CFO attributed the upgrades to successful execution of its growth strategy and improved financial profile.